GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (FRA:07X) » Definitions » Current Accrued Expense

Annovis Bio (FRA:07X) Current Accrued Expense : €1.05 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Annovis Bio Current Accrued Expense?

Annovis Bio's Current Accrued Expense for the quarter that ended in Mar. 2025 was €1.05 Mil.

Annovis Bio's quarterly Current Accrued Expense increased from Sep. 2024 (€1.16 Mil) to Dec. 2024 (€1.50 Mil) but then declined from Dec. 2024 (€1.50 Mil) to Mar. 2025 (€1.05 Mil).

Annovis Bio's annual Current Accrued Expense declined from Dec. 2022 (€3.53 Mil) to Dec. 2023 (€2.74 Mil) and declined from Dec. 2023 (€2.74 Mil) to Dec. 2024 (€1.50 Mil).


Annovis Bio Current Accrued Expense Historical Data

The historical data trend for Annovis Bio's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annovis Bio Current Accrued Expense Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Accrued Expense
Get a 7-Day Free Trial 0.19 0.73 3.53 2.74 1.50

Annovis Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.62 1.16 1.50 1.05

Annovis Bio Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Annovis Bio Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Annovis Bio's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Annovis Bio Business Description

Traded in Other Exchanges
Address
101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.

Annovis Bio Headlines

No Headlines